Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Priya Mehta, Pooja Sapovadia, Bhargav Purohit
{"title":"Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report.","authors":"Priya Mehta, Pooja Sapovadia, Bhargav Purohit","doi":"10.2174/0115748863337946250101110356","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clomipramine, a Tricyclic Antidepressant (TCA), is known for its efficacy in treating Obsessive-compulsive Disorder (OCD). However, it is associated with several side effects, including urinary retention. This case report discusses the case of a 20-year-old male with OCD who developed urinary retention following clomipramine administration.</p><p><strong>Case representation: </strong>A 20-year-old male with a one-year history of OCD with psychotic features was admitted to SIR-T Hospital, Bhavnagar, due to worsening symptoms. He was prescribed clomipramine along with other psychotropic medications. On the 16th day of hospitalization, the patient experienced acute urinary retention, necessitating catheterization. Clomipramine dosage was subsequently reduced, resulting in the resolution of urinary retention. The patient was discharged after 29 days with no further urinary complications.</p><p><strong>Discussion: </strong>The causality assessment suggested a probable link between clomipramine and urinary retention, supported by the Naranjo Scale, WHO-UMC criteria, and literature. The anticholinergic properties of clomipramine likely contributed to the condition. Despite its side effects, clomipramine remains a valuable treatment for OCD, requiring careful dose management to mitigate adverse effects.</p><p><strong>Conclusion: </strong>Clinicians should be vigilant for urinary retention in patients receiving clomipramine, especially at higher doses. Regular monitoring and dose adjustments are crucial for managing this side effect without compromising the therapeutic benefits for OCD.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863337946250101110356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clomipramine, a Tricyclic Antidepressant (TCA), is known for its efficacy in treating Obsessive-compulsive Disorder (OCD). However, it is associated with several side effects, including urinary retention. This case report discusses the case of a 20-year-old male with OCD who developed urinary retention following clomipramine administration.

Case representation: A 20-year-old male with a one-year history of OCD with psychotic features was admitted to SIR-T Hospital, Bhavnagar, due to worsening symptoms. He was prescribed clomipramine along with other psychotropic medications. On the 16th day of hospitalization, the patient experienced acute urinary retention, necessitating catheterization. Clomipramine dosage was subsequently reduced, resulting in the resolution of urinary retention. The patient was discharged after 29 days with no further urinary complications.

Discussion: The causality assessment suggested a probable link between clomipramine and urinary retention, supported by the Naranjo Scale, WHO-UMC criteria, and literature. The anticholinergic properties of clomipramine likely contributed to the condition. Despite its side effects, clomipramine remains a valuable treatment for OCD, requiring careful dose management to mitigate adverse effects.

Conclusion: Clinicians should be vigilant for urinary retention in patients receiving clomipramine, especially at higher doses. Regular monitoring and dose adjustments are crucial for managing this side effect without compromising the therapeutic benefits for OCD.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信